Lombardi P, Ramon-Gil E, Raja RQ, Brunetti L, Manfredi GF, Zhou Z, Merces G, Cappuyns S, Fulgenzi CAM, D'Alessio A, Torkpour A, Celsa C, Stefanini B, Yang H, Crowley F, Marron TU, Saeed A, Pinter M, Scheiner B, Huang YH, Lee PC, Nishida N, Po-Ting Lin R, Dalbeni A, Vivaldi C et al. (2026)
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma
J Hepatol (in press)
DOI 10.1016/j.jhep.2026.05.018, PubMed 42297215

Hektoen HH, Tsuruda KM, Mæhlen MT, Helland Å, Andreassen BK (2026)
Real-world outcomes of immunotherapy in advanced NSCLC patients with comorbidities
Br J Cancer (in press)
DOI 10.1038/s41416-026-03491-1, PubMed 42259946

Carlsen IH, Dyvik VR, Johannessen TB, Fjellanger K, Sandvik IM, Hjørnevik JV, Sulen TH, Nybø T, Hundvin JA, Pilskog SMC, Fløtten Ø, Haakensen VD, Hysing LB (2026)
Prospective evaluation and clinical outcomes of adaptive radiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC)
Acta Oncol, 65, 476-484
DOI 10.2340/1651-226X.2026.45745, PubMed 42200217